UBS’s Orexigen Therapeutics, Inc. OREX Stock Holding History

UBS’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$510K	Sell	11,978 -1,682	-12%	-$90.3K	﹤0.01%	4259
2014 Q2	$845K	Sell	13,660 -1,711	-11%	-$99.5K	﹤0.01%	3714
2014 Q1	$999K	Buy	15,371 +1,691	+12%	+$114K	﹤0.01%	3489
2013 Q4	$770K	Buy	13,680 +1,475	+12%	+$82.9K	﹤0.01%	3831
2013 Q3	$748K	Sell	12,205 -563	-4%	-$38.1K	﹤0.01%	3682
2013 Q2	$746K	Buy	+12,768	New	+$785K	﹤0.01%	3643

Other funds holding OREX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS's OREX Position: Q3 2014 in Review

UBS reduced its Orexigen Therapeutics, Inc. (OREX) stake by 12% in Q3 2014, selling an estimated $90.3K and leaving 11,978 shares worth $510K. The position accounts for ﹤0.01% of the portfolio, ranked #4259.

UBS first reported a position in OREX in Q2 2013 and has held it in 6 quarters since. The position peaked at $999K in Q1 2014. 128 funds tracked by Wall St. Rank hold OREX as of Q3 2014.

UBS held 11,978 shares of Orexigen Therapeutics, Inc. worth $510K as of Q3 2014.
UBS sold 1,682 Orexigen Therapeutics, Inc. shares in Q3 2014, an estimated $90.3K.
Orexigen Therapeutics, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #4259 holding.
UBS first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and has held it in 6 quarters since.
UBS's Orexigen Therapeutics, Inc. position peaked at $999K in Q1 2014.
128 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.